PURPOSE: To investigate the influence of personality traits, depression, and training on objectively measured adherence to once-daily prostaglandin analog medication. METHODS: Adherence was measured with the Travalert Dosing Aid on 58 consecutive, regularly followed-up glaucoma patients already on self-administered travoprost. Before the 3-month data-collection period all patients received training on use of the device. Psychologic characteristics were measured using the State-Trait Anxiety Inventory, Eysenck Personality Questionnaire, and Beck Hopeless Scale and Depression Inventory. An adherent day was defined as travoprost instillation at 9 PM +/-2 hours. RESULTS: Adherence was 77% for the total period. Social desirability was higher than normal (U test, P<0.0001). Seven patients (12.1%) showed mild-to-moderate depression, which was not significantly associated with decreased adherence (Kruskal-Wallis test, P=0.071). Severity of glaucoma, number of ocular and systemic medications, satisfaction with the recording device, and socio-economic characteristics had no influence on adherence. CONCLUSIONS: Objectively measured adherence to once-daily prostaglandin analog medication was good, and not influenced by treatment characteristics or patient factors including mild-to-moderate depression. The elevated social desirability suggests that self-reported adherence is not a reliable measure of adherence in glaucoma.
PURPOSE: To investigate the influence of personality traits, depression, and training on objectively measured adherence to once-daily prostaglandin analog medication. METHODS: Adherence was measured with the Travalert Dosing Aid on 58 consecutive, regularly followed-up glaucomapatients already on self-administered travoprost. Before the 3-month data-collection period all patients received training on use of the device. Psychologic characteristics were measured using the State-Trait Anxiety Inventory, Eysenck Personality Questionnaire, and Beck Hopeless Scale and Depression Inventory. An adherent day was defined as travoprost instillation at 9 PM +/-2 hours. RESULTS: Adherence was 77% for the total period. Social desirability was higher than normal (U test, P<0.0001). Seven patients (12.1%) showed mild-to-moderate depression, which was not significantly associated with decreased adherence (Kruskal-Wallis test, P=0.071). Severity of glaucoma, number of ocular and systemic medications, satisfaction with the recording device, and socio-economic characteristics had no influence on adherence. CONCLUSIONS: Objectively measured adherence to once-daily prostaglandin analog medication was good, and not influenced by treatment characteristics or patient factors including mild-to-moderate depression. The elevated social desirability suggests that self-reported adherence is not a reliable measure of adherence in glaucoma.
Authors: Catherine Slota; Robyn Sayner; Michelle Vitko; Delesha M Carpenter; Susan J Blalock; Alan L Robin; Kelly W Muir; Mary Elizabeth Hartnett; Betsy Sleath Journal: Optom Vis Sci Date: 2015-05 Impact factor: 1.973
Authors: Qi Zhang; Helen Vuong; Xin Huang; YanLing Wang; Nicholas C Brecha; MingLiang Pu; Jie Gao Journal: Sci China Life Sci Date: 2013-06-01 Impact factor: 6.038
Authors: Catherine Slota; Scott A Davis; Susan J Blalock; Delesha M Carpenter; Kelly W Muir; Alan L Robin; Betsy Sleath Journal: Optom Vis Sci Date: 2017-12 Impact factor: 1.973
Authors: Cliff Richardson; Lisa Brunton; Nicola Olleveant; David B Henson; Mark Pilling; Jane Mottershead; Cecilia H Fenerty; Anne Fiona Spencer; Heather Waterman Journal: Patient Prefer Adherence Date: 2013-10-07 Impact factor: 2.711